- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Michael Chernew, PhD, Discusses Challenges in Oncology Management
Michael Chernew, PhD, Professor of Health Care Policy, Harvard Medical School, Vice Chairman, MEDPAC, Co-Editor-in-Chief, The American Journal of Managed Care, says that patients want access to expensive drugs that can help expand and improve their lives.
Professor of Health Care Policy,
Harvard Medical School,
Vice Chairman, MEDPAC,
Co-Editor-in-Chief, The American Journal of Managed Care, says that patients want access to expensive drugs that can help expand and improve their lives. A big challenge is understanding which of these drugs are valuable while managing their use. Dr. Chernew says determining what is high and low value is one of the biggest challenges payers face in oncology management.
Michael Chernew, PhD,
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
Legal Navigation Services Key to Addressing Disparities in Cancer Care
July 31st 2025A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More
